Friday, July 10, 2026

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Clinical program

BN44620

Approved · small molecule · Spinal Muscular Atrophy (SMA)

BN44620 for Spinal Muscular Atrophy (SMA) is a Approved program (small_molecule) at Hoffmann-La Roche with 1 ClinicalTrials.gov record(s).

← All Hoffmann-La Roche projects Approved small molecule active

Internal code BN44620

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoffmann-La Roche
Phase
Approved
Modality
small_molecule
Indication
Spinal Muscular Atrophy (SMA)
Status
active
Trials
1